The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model

Tamar Tadmor, Yu Zhang, Hyun Mi Cho, Eckhard R. Podack, Joseph D Rosenblatt

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Increasing evidence suggests that B lymphocytes play a central role in inhibiting the immune response against certain tumors, but the underlying mechanisms by which B cells facilitate tumor growth are still poorly understood. In this study, we investigated how the presence or absence of B cells affects expansion and function of T-regulatory cells ('T-regs') in a murine breast tumor model (EMT-6). We compared tumor growth, and the number and function of T-reg cells in wild-type immune-competent mice (ICM) and B-cell-deficient mice (BCDM). Mice were either tumor-naive or implanted with EMT-6 mammary adenocarcinoma cells. Tumor growth was markedly inhibited in BCDM, compared to wild-type mice (ICM). Increased T-reg expansion as defined by CD4+/CD25+/FOXP3+ cells was evident following EMT-6 inoculation in ICM in comparison with non-tumor-bearing mice or compared to BCDM in which tumor had been implanted. The percentage and absolute number of T-regs in the spleen, tumor draining lymph nodes, and tumor bed were significantly reduced in BCDM compared to ICM. T-reg function, measured by suppression and proliferation assays, was also reduced in tumor inoculated BCDM compared to ICM. Our studies indicate that absence of B cells may play a role in augmenting the T-cell anti-tumor response, in part due to effects on T-regulatory cell expansion and function.

Original languageEnglish
Pages (from-to)609-619
Number of pages11
JournalCancer Immunology, Immunotherapy
Volume60
Issue number5
DOIs
StatePublished - May 1 2011

Fingerprint

Lymphocyte Count
Regulatory T-Lymphocytes
B-Lymphocytes
Neoplasms
Growth
Adenocarcinoma
Breast
Spleen
Lymph Nodes

Keywords

  • Anti-tumor immunity
  • B lymphocyte
  • B-cell-deficient mice (BCDM)
  • Immune-competent mice (ICM)
  • T-regulatory cells (T-reg)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. / Tadmor, Tamar; Zhang, Yu; Cho, Hyun Mi; Podack, Eckhard R.; Rosenblatt, Joseph D.

In: Cancer Immunology, Immunotherapy, Vol. 60, No. 5, 01.05.2011, p. 609-619.

Research output: Contribution to journalArticle

@article{5f7d6e29fa7144ea882b898b288a33d1,
title = "The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model",
abstract = "Increasing evidence suggests that B lymphocytes play a central role in inhibiting the immune response against certain tumors, but the underlying mechanisms by which B cells facilitate tumor growth are still poorly understood. In this study, we investigated how the presence or absence of B cells affects expansion and function of T-regulatory cells ('T-regs') in a murine breast tumor model (EMT-6). We compared tumor growth, and the number and function of T-reg cells in wild-type immune-competent mice (ICM) and B-cell-deficient mice (BCDM). Mice were either tumor-naive or implanted with EMT-6 mammary adenocarcinoma cells. Tumor growth was markedly inhibited in BCDM, compared to wild-type mice (ICM). Increased T-reg expansion as defined by CD4+/CD25+/FOXP3+ cells was evident following EMT-6 inoculation in ICM in comparison with non-tumor-bearing mice or compared to BCDM in which tumor had been implanted. The percentage and absolute number of T-regs in the spleen, tumor draining lymph nodes, and tumor bed were significantly reduced in BCDM compared to ICM. T-reg function, measured by suppression and proliferation assays, was also reduced in tumor inoculated BCDM compared to ICM. Our studies indicate that absence of B cells may play a role in augmenting the T-cell anti-tumor response, in part due to effects on T-regulatory cell expansion and function.",
keywords = "Anti-tumor immunity, B lymphocyte, B-cell-deficient mice (BCDM), Immune-competent mice (ICM), T-regulatory cells (T-reg)",
author = "Tamar Tadmor and Yu Zhang and Cho, {Hyun Mi} and Podack, {Eckhard R.} and Rosenblatt, {Joseph D}",
year = "2011",
month = "5",
day = "1",
doi = "10.1007/s00262-011-0972-z",
language = "English",
volume = "60",
pages = "609--619",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "5",

}

TY - JOUR

T1 - The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model

AU - Tadmor, Tamar

AU - Zhang, Yu

AU - Cho, Hyun Mi

AU - Podack, Eckhard R.

AU - Rosenblatt, Joseph D

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Increasing evidence suggests that B lymphocytes play a central role in inhibiting the immune response against certain tumors, but the underlying mechanisms by which B cells facilitate tumor growth are still poorly understood. In this study, we investigated how the presence or absence of B cells affects expansion and function of T-regulatory cells ('T-regs') in a murine breast tumor model (EMT-6). We compared tumor growth, and the number and function of T-reg cells in wild-type immune-competent mice (ICM) and B-cell-deficient mice (BCDM). Mice were either tumor-naive or implanted with EMT-6 mammary adenocarcinoma cells. Tumor growth was markedly inhibited in BCDM, compared to wild-type mice (ICM). Increased T-reg expansion as defined by CD4+/CD25+/FOXP3+ cells was evident following EMT-6 inoculation in ICM in comparison with non-tumor-bearing mice or compared to BCDM in which tumor had been implanted. The percentage and absolute number of T-regs in the spleen, tumor draining lymph nodes, and tumor bed were significantly reduced in BCDM compared to ICM. T-reg function, measured by suppression and proliferation assays, was also reduced in tumor inoculated BCDM compared to ICM. Our studies indicate that absence of B cells may play a role in augmenting the T-cell anti-tumor response, in part due to effects on T-regulatory cell expansion and function.

AB - Increasing evidence suggests that B lymphocytes play a central role in inhibiting the immune response against certain tumors, but the underlying mechanisms by which B cells facilitate tumor growth are still poorly understood. In this study, we investigated how the presence or absence of B cells affects expansion and function of T-regulatory cells ('T-regs') in a murine breast tumor model (EMT-6). We compared tumor growth, and the number and function of T-reg cells in wild-type immune-competent mice (ICM) and B-cell-deficient mice (BCDM). Mice were either tumor-naive or implanted with EMT-6 mammary adenocarcinoma cells. Tumor growth was markedly inhibited in BCDM, compared to wild-type mice (ICM). Increased T-reg expansion as defined by CD4+/CD25+/FOXP3+ cells was evident following EMT-6 inoculation in ICM in comparison with non-tumor-bearing mice or compared to BCDM in which tumor had been implanted. The percentage and absolute number of T-regs in the spleen, tumor draining lymph nodes, and tumor bed were significantly reduced in BCDM compared to ICM. T-reg function, measured by suppression and proliferation assays, was also reduced in tumor inoculated BCDM compared to ICM. Our studies indicate that absence of B cells may play a role in augmenting the T-cell anti-tumor response, in part due to effects on T-regulatory cell expansion and function.

KW - Anti-tumor immunity

KW - B lymphocyte

KW - B-cell-deficient mice (BCDM)

KW - Immune-competent mice (ICM)

KW - T-regulatory cells (T-reg)

UR - http://www.scopus.com/inward/record.url?scp=79955539126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955539126&partnerID=8YFLogxK

U2 - 10.1007/s00262-011-0972-z

DO - 10.1007/s00262-011-0972-z

M3 - Article

C2 - 21253724

AN - SCOPUS:79955539126

VL - 60

SP - 609

EP - 619

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 5

ER -